Anti-SARS-CoV-2 receptor binding domain antibodies after the second dose of Sinovac and AstraZeneca vaccination
10.7774/cevr.2023.12.3.224
- Author:
Marisca Evalina GONDOKESUMO
1
;
Anita PURNAMAYANTI
;
Puri Safitri HANUM
;
Winnie Nirmala SANTOSA
;
Ardyan Prima WARDHANA
;
Christina AVANTI
Author Information
1. Faculty of Pharmacy, University of Surabaya, Surabaya, Indonesia
- Publication Type:Original article
- From:Clinical and Experimental Vaccine Research
2023;12(3):224-231
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:The Sinovac and AstraZeneca vaccines are the primary coronavirus disease 2019 vaccines in Indonesia. Antibody levels in vaccine-injected individuals will decline substantially over time, but data supporting the duration of such responses are limited. Therefore, this study aims to quantitatively evaluate antibody responses resulting from the completion of Sinovac and AstraZeneca administration in Indonesian adults.
Materials and Methods:Participants were divided into two groups based on their vaccine type. Both groups were then assessed on the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding domain (anti-SRBD) concentrations. The anti-SRBD level was measured using Elecsys anti-SARS-CoV-2 S assay and analyzed every month until 3 months after the second vaccination.
Results:The results presented significant differences (p=0.000) in immunoglobulin G (IgG) titers among the vaccines’ measurement duration, where all samples observed a decrease in IgG titers over time. The mean titer levels of anti-SRBD IgG in the group given Sinovac were high in the first month after vaccination and decreased by 55.7% in 3 months. AstraZeneca showed lesser immune response with a slower decline rate. Adverse effects following immunization (AEFI) showed that systemic reactions are the most reported in both vaccines, with a higher percentage in the second dose of AstraZeneca type vaccines.
Conclusion:Sinovac induced more significant titers of anti-SRBD IgG 1 month after the second dose but generated fewer AEFIs. In contrast, AstraZeneca generated more AEFIs, in mild to moderate severity, but provided lower levels of anti-SRBD IgG.
